Abstract: A sensor sheath for a catheter. The sensor sheath includes a substrate having at least one sensor associated therewith; and an electronics unit in communication with at the at least one sensor, wherein the substrate is configured to attach to a catheter.

Abstract: A sensor sheath for a catheter. The sensor sheath includes a substrate having at least one sensor associated therewith and an electronics unit in communication with the at least one sensor, wherein the substrate is configured to attach to a catheter.

Abstract: A sensor sheath for a catheter. The sensor sheath includes a substrate having at least one sensor associated therewith; and an electronics unit in communication with at the at least one sensor, wherein the substrate is configured to attach to a catheter.

Abstract: MRI-guided high-intensity focused ultrasound (“HIFU”) therapy can be used to ablate sympathetic nerves near the renal arteries. Such therapy may employ a HIFU device that includes an ultrasound transducer and an expandable reservoir that includes a first surface configured to conform to a surface anatomy of a patient and a port in fluid communication with a fluid source. The expandable reservoir can be configured to change a size in a dimension by inflating or deflating the expandable reservoir. Such a device may be used in connection with an MRI device that includes a support portion configured to conform to the surface anatomy of the patient and defining a first window configured to receive the ultrasound transducer for targeting tissue. The MRI device can include radiofrequency coil arrays embedded throughout to the support portion to monitor the therapy.

Abstract: Non-invasive, outcome-confirmed renal denervation procedures include assessments performed before, during, and after an ablation procedure. Stimulation operations can be performed by ultrasound application apart from ablation and/or heating operations to determine the presence and/or condition of a renal nerve in a targeted region. Consistent nerve ablation can be achieved (e.g., in a spontaneous hypertensive patient) by assessing the pathophysiology of renal denervation via (1) reduction of blood pressure and/or (2) kidney and serum norepinephrine concentration.

Abstract: Some embodiments of the invention relate to a system for treating tissue internal to a body, such as heart tissue. For example, the system may be used to ablate tissue as a treatment for atrial fibrillation. In certain embodiments, the system is capable of causing scar tissue to form in ostial areas of the atrium rather than inside the pulmonary vein. In such embodiments, the system may include a tissue treatment member that is operable to form an annular area of ablated tissue along the outer portion of the ostium in an area known as the antrum.

Abstract: Some embodiments of the invention relate to a system for treating tissue internal to a body, such as heart tissue. For example, the system may be used to ablate tissue as a treatment for atrial fibrillation. In certain embodiments, the system is capable of causing scar tissue to form in ostial areas of the atrium rather than inside the pulmonary vein. In such embodiments, the system may include a tissue treatment member that is operable to form an annular area of ablated tissue along the outer portion of the ostium in an area known as the antrum.

Abstract: Some embodiments of the invention relate to a system for treating tissue internal to a body, such as heart tissue. For example, the system may be used to ablate tissue as a treatment for atrial fibrillation. In certain embodiments, the system is capable of causing scar tissue to form in ostial areas of the atrium rather than inside the pulmonary vein. In such embodiments, the system may include a tissue treatment member that is operable to form an annular area of ablated tissue along the outer portion of the ostium in an area known as the antrum.

Abstract: Some embodiments of the invention relate to a system for treating tissue internal to a body, such as heart tissue. For example, the system may be used to ablate tissue as a treatment for atrial fibrillation. In certain embodiments, the system is capable of causing scar tissue to form in ostial areas of the atrium rather than inside the pulmonary vein. In such embodiments, the system may include a tissue treatment member that is operable to form an annular area of ablated tissue along the outer portion of the ostium in an area known as the antrum.